Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,290 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07161544RecruitingPhase 1/Phase 2
Gene therapy for Stargardt disease
This trial tests a new gene therapy, AAVB-039, for people with Stargardt disease caused by a specific gene mutation. The treatment is given during eye surgery and aims to slow or stop vision loss.
Phoenix, ArizonaAges 8–55 - NCT07161700Enrolling by invitationPhase 2
Long-term safety study of SPT-300 for major depression
This study is for people who finished the earlier BUOY-1 study of SPT-300 and want to continue treatment. It tests the long-term safety and tolerability of SPT-300 for major depressive disorder, with or without anxious distress.
Chino, CaliforniaAges 18–66 - NCT07156201RecruitingPhase 1
Safety study of oral ABS-1230 in healthy adults
This trial tests a new oral medication called ABS-1230 in healthy people to see how safe it is and how the body processes it. You would take either the drug or a placebo (no active ingredient) and be monitored closely.
Sydney, New South WalesAges 18–55 - NCT07160725RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial is testing a new drug (BMS-986517) for people with advanced solid tumors, including certain lung, head and neck, and breast cancers. The goal is to see if the drug is safe and effective.
Irvine, CaliforniaAges 18 years+ - NCT07160205RecruitingPhase 2/Phase 3
Study of ULSC for dermatomyositis and polymyositis
This trial tests a new treatment called ULSC to see if it can improve muscle strength and skin symptoms, and help reduce steroid use in people with dermatomyositis or polymyositis. It may be an option if standard treatments haven't worked well enough.
Gainesville, FloridaAges 18 years+ - NCT07157787RecruitingPhase 2
Testing a new drug for primary membranous nephropathy
This trial tests a new drug called ALXN1920 for adults with primary membranous nephropathy (PMN), a kidney disease where the immune system attacks the kidneys. It is for people at high risk of their disease getting worse, and it compares the new drug added to standard care versus standard care alone.
Loma Linda, CaliforniaAges 18–75 - NCT07159126RecruitingPhase 1
Study of DS3610a for advanced solid tumors
This trial tests a new drug called DS3610a for people with advanced solid tumors that have stopped responding to other treatments. You may be able to join if you have tried standard therapies and are willing to provide a tumor sample.
Milwaukee, WisconsinAges 18 years+ - NCT07160179RecruitingPhase 1/Phase 2
Study of an eye injection for geographic atrophy
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
Carmel, IndianaAges 50 years+ - NCT07162116RecruitingPhase 1
Effect of XY0206 on heart rhythm in healthy Chinese volunteers
This trial tests whether a new drug called XY0206 affects the heart's electrical activity (QTc interval). Healthy participants take either XY0206, a placebo, or a control drug to compare effects. It helps ensure the drug is safe for the heart before testing in patients.
Zibo, ShandongAges 18–45 - NCT07164313RecruitingPhase 1
ZW251 for advanced solid tumors
This trial is testing a new drug called ZW251 for people with advanced liver cancer (hepatocellular carcinoma), non-small cell lung cancer, or germ cell tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT06949982RecruitingPhase 2
Comparing two treatments for advanced colorectal cancer with RAS mutations
This trial tests if a combination of hydroxychloroquine, methotrexate, capecitabine, and bevacizumab works better than regorafenib for people with metastatic colorectal cancer that has a RAS gene mutation and has stopped responding to at least two prior treatments.
Saint Petersburg, Sankt-PeterburgAges 18 years+ - NCT07153172RecruitingPhase 1
Safety follow-up for people who got INV-347
This study checks on the long-term safety of people who already received the study drug INV-347 in a previous trial. You'll have your blood tested to see how much of the drug is still in your system.
QuébecAges 18 years+ - NCT07154290RecruitingPhase 2
Ubamatamab with or without REGN7075 for advanced lung cancer
This trial tests a new targeted therapy (ubamatamab) alone or with another drug (REGN7075) for people with advanced or metastatic non-small cell lung cancer that has gotten worse after standard treatment. It aims to see if targeting MUC16, a substance found on some cancer cells, can help control the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07145151RecruitingPhase 2
Studying UBT251 for MASH liver disease
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
Beijing, Beijing MunicipalityAges 18–75 - NCT07145229RecruitingPhase 2
Testing a new drug for acute gout flares
This trial tests a new medication, ABP-745, for people having an acute gout flare. It aims to see if the drug is safe and helps reduce pain and inflammation.
Peoria, ArizonaAges 18–70 - NCT07146100Recruiting
Long-term follow-up after AHB-137 treatment for hepatitis B
This study follows participants with chronic hepatitis B who previously responded to the drug AHB-137. The goal is to track long-term health and safety after their treatment.
Hefei, AnhuiAges 18 years+ - NCT07145918RecruitingPhase 2
Study of an oral schizophrenia drug for adults
This trial tests an experimental oral drug (emraclidine) to see if it helps symptoms of schizophrenia and how it moves through the body. It looks at two groups of participants: those with stable symptoms and those having an acute flare-up.
Little Rock, ArkansasAges 18–65 - NCT07155174RecruitingPhase 2
Testing new drug combo for first-line extensive small cell lung cancer
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
New Haven, ConnecticutAges 18 years+ - NCT07146646RecruitingPhase 2
Chemo combo for advanced bile duct cancer
This trial tests a combination of two chemotherapy drugs (trifluridine/tipiracil and oxaliplatin) for people with advanced or metastatic bile duct cancer (including gallbladder cancer) who have only had one prior treatment. The goal is to see if this combination can help control the cancer.
Cleveland, OhioAges 19 years+ - NCT07140809RecruitingPhase 1/Phase 2
Study of JMT202 for people with high triglycerides
This trial tests a new injectable drug, JMT202, for people with high triglycerides (a type of fat in the blood). The goal is to see if it safely lowers triglycerides and may reduce heart risk.
Beijing, Beijing MunicipalityAges 18–75 - NCT07140783RecruitingPhase 3
Eye drops to improve night vision after laser eye surgery
This study tests an eye drop that may help people who had laser eye surgery before 2010 and now have trouble seeing in dim light, such as glare, halos, or starbursts at night. The drops are given at home and may improve vision in low light.
Chandler, ArizonaAges 18 years+ - NCT07142707RecruitingPhase 1
Testing a new obesity drug for safety and effects
This study tests an investigational medication called MBX 4291 for adults with obesity. It aims to see if the drug is safe and how it works in the body, which could lead to a new weight-loss treatment option.
Doral, FloridaAges 18–65 - NCT07140900RecruitingPhase 1
Study of xaluritamig combined with hormone therapy for advanced prostate cancer
This trial tests a new drug, xaluritamig, given with standard hormone therapy for men with prostate cancer that has spread to other parts of the body (metastatic) and is still sensitive to hormone therapy. It aims to see if the combination is safe and works better than hormone therapy alone.
San Francisco, CaliforniaAges 18 years+ - NCT07142343RecruitingPhase 4
Testing pozelimab safety in young children with CHAPLE disease
This trial tests if pozelimab is safe for children aged 1 to 5 with CHAPLE disease, a rare condition that causes swelling, blood clots, and protein loss. If your child has active CHAPLE disease, this study may offer a new treatment option.
IstanbulAges 1–5
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,290 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.